Stifel on Thursday initiated coverage on Definium Therapeutics Inc. DFTX, highlighting significant potential for its lead ...
Digital anxiety results from info overload. AI wearables, brief exercise, and mindfulness help manage cognitive fatigue and ...
There is a new wave of psychedelic treatment moving through clinical trials targeting mental health conditions, and they are showing strong efficacy. Ben Hargreaves finds that certain treatments are ...
Rep. Alexandria Ocasio-Cortez (D-NY) tore into the current U.S. drug scheduling system on Thursday—making the case that placing substances like marijuana and LSD in the most restrictive category runs ...
Psychedelic stocks focus on hallucinogenic treatments, carrying significant growth potential but high volatility. Recent clinical trials show promise in treating depression and anxiety, boosting ...
Swiss neurotech firm MindMaze Therapeutics and US provider Vibra Healthcare have reported real-world evidence suggesting technology-enabled, high-dose therapy can improve recovery outcomes for stroke ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results